Table 3.
Summary of study characteristics included in meta-analysis
| Characteristic | No. of Studies* | Value or Proportion Across Studies | |
|---|---|---|---|
| Median | Range | ||
| Patient age, years | 20 | 53.7 | 43.0–62.1 |
| Type of IBTR | |||
| DCIS | 17 | 50.0% | 0.0%–75.0% |
| Invasive | 17 | 50.0% | 25.0%–100.0% |
| Unknown | 17 | 0.0% | 0.0%–7.1% |
| Screen detected | |||
| Yes | 14 | 85.8% | 45.6%–100.0% |
| No | 14 | 14.2% | 0.0%–54.4% |
| Unknown | 14 | 0.0% | 0.0%–2.8% |
| Grade | |||
| I | 13 | 17.5% | 1.8%–64.5% |
| II | 13 | 28.0% | 5.5%–45.0% |
| I–II | 16 | 57.3% | 7.3%–92.5% |
| III | 16 | 28.4% | 3.5%–45.6% |
| Unknown | 16 | 9.2% | 0.0%–87.3% |
| Hormone receptor status | |||
| Positive | 5 | 50.4% | 23.0%–80.4% |
| Negative | 5 | 8.7% | 2.8%–14.3% |
| Unknown | 5 | 40.9% | 14.8%–69.8% |
| Median WBRT dose, Gy | 11 | 50.0 | 42.5–50.0 |
| Radiation boost | 19 | 70.9% | 0.0%–100% |
| Median boost dose, Gy | 8 | 10.0 | 10.0-10.8 |
NOTE. Data adapted.16
Abbreviations: DCIS, ductal carcinoma in situ; IBTR, ipsilateral breast tumor recurrence; WBRT, whole-breast irradiation
*Refers to studies contributing information on the characteristic, including studies with subsets of patients missing data for the characteristic